TY - JOUR
T1 - Neuritogenic effect of standardized extract of Centella asiatica ECa233 on human neuroblastoma cells
AU - Wanakhachornkrai, Oraphan
AU - Pongrakhananon, Varisa
AU - Chunhacha, Preedakorn
AU - Wanasuntronwong, Aree
AU - Vattanajun, Anusara
AU - Tantisira, Boonyong
AU - Chanvorachote, Pithi
AU - Tantisira, Mayuree H.
N1 - Funding Information:
The work was supported by The 90thAnniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) and Ratchadaphiseksom-phot Endowment Fund for Cell-based Drug and Health Product Development Research Unit. The authors would like to thank Associate Professor Ekarin Saifah and collaborates for the provision of ECa 233.
PY - 2013/8/4
Y1 - 2013/8/4
N2 - Background: In order to gain insight into neuroprotective effects of ECa 233, a standardized extract of Centella asiatica, previously demonstrated in animal models of memory impairment induced by transient global ischemia or intracerebroventricular injection of β-amyloid, the effect of ECa 233 on neurite outgrowth of human IMR-32 neuroblastoma cell line was investigated.Methods: Cells were seeded and incubated with various concentrations of ECa 233. Morphometric analysis was carried out by a measurement of the longest neurite growth of cells at 24 and 48 h. Contributing signaling pathways possibly involved were subsequently elucidated by western blot analysis.Results: While ECa 233 had only limited effects on cell viability, it significantly enhanced neurite outgrowth of IMR-32 cells at the concentrations of 1-100 μg/ml. Western blot analysis revealed that ECa 233 significantly upregulated the level of activated ERK1/2 and Akt of the treated cells suggesting their involvement in the neuritogenic effect observed, which was subsequently verified by the finding that an addition of their respective inhibitors could reverse the effect of ECa 233 on these cells.Conclusions: The present study clearly demonstrated neurite outgrowth promoting activity of ECa 233. ERK1/2 and Akt signaling pathways seemed to account for the neurotrophic effect observed. In conjunction with in vivo neuroprotective effect of ECa 233 previously reported, the results obtained support further development of ECa 233 for clinical use in neuronal injury or neurodegenerative diseases.
AB - Background: In order to gain insight into neuroprotective effects of ECa 233, a standardized extract of Centella asiatica, previously demonstrated in animal models of memory impairment induced by transient global ischemia or intracerebroventricular injection of β-amyloid, the effect of ECa 233 on neurite outgrowth of human IMR-32 neuroblastoma cell line was investigated.Methods: Cells were seeded and incubated with various concentrations of ECa 233. Morphometric analysis was carried out by a measurement of the longest neurite growth of cells at 24 and 48 h. Contributing signaling pathways possibly involved were subsequently elucidated by western blot analysis.Results: While ECa 233 had only limited effects on cell viability, it significantly enhanced neurite outgrowth of IMR-32 cells at the concentrations of 1-100 μg/ml. Western blot analysis revealed that ECa 233 significantly upregulated the level of activated ERK1/2 and Akt of the treated cells suggesting their involvement in the neuritogenic effect observed, which was subsequently verified by the finding that an addition of their respective inhibitors could reverse the effect of ECa 233 on these cells.Conclusions: The present study clearly demonstrated neurite outgrowth promoting activity of ECa 233. ERK1/2 and Akt signaling pathways seemed to account for the neurotrophic effect observed. In conjunction with in vivo neuroprotective effect of ECa 233 previously reported, the results obtained support further development of ECa 233 for clinical use in neuronal injury or neurodegenerative diseases.
KW - Akt
KW - Centella asiatica
KW - ECa 233
KW - ERK1/2
KW - IMR-32 neuroblastoma
KW - Neurite outgrowth
UR - http://www.scopus.com/inward/record.url?scp=84880940160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880940160&partnerID=8YFLogxK
U2 - 10.1186/1472-6882-13-204
DO - 10.1186/1472-6882-13-204
M3 - Article
C2 - 23915016
AN - SCOPUS:84880940160
SN - 1472-6882
VL - 13
JO - BMC Complementary and Alternative Medicine
JF - BMC Complementary and Alternative Medicine
M1 - 204
ER -